Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 plus Mitotane in Adrenocortical Carcinoma
NCT00778817Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2008
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cixutumumab in adrenocortical carcinoma (ACC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival Rate at 18 weeks. Started Dec 2008; status: terminated.
02
Drugs
cixutumumab
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00778817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778817.